Methylxanthine therapy for apnea of prematurity

Evaluation of treatment benefits and risks at age 5 years in the international Caffeine for Apnea of Prematurity (CAP) trial

Barbara Schmidt, for the CAP 5-Year Steering Committee

Research output: Contribution to journalReview ArticleResearchpeer-review

39 Citations (Scopus)

Abstract

Methylxanthine therapy reduces the frequency of apnea and the need for mechanical ventilation. Recent research has raised concerns about the safety of methylxanthines in very preterm infants. Possible adverse effects include poor growth, worsening of hypoxic-ischemic brain damage and abnormal childhood behavior. Over 2,000 infants with birth weights 500-1,250 g have been randomized in the international placebo-controlled Caffeine for Apnea of Prematurity (CAP) trial to examine the long-term efficacy and safety of methylxanthine therapy for the management of apnea of prematurity. Additional therapies such as continuous positive airway pressure were used as necessary to control apneic attacks. At 18 months we measure the combined rate of death or survival with one or more of the following impairments: cerebral palsy, cognitive deficit, blindness and deafness. This outcome was chosen because of the need to evaluate the impact of common neonatal therapies beyond discharge from the intensive care unit. However, several potential long-term consequences of methylxanthine therapy may not become apparent until the study cohort reaches pre-school age. We will therefore extend the follow-up to age 5 years. The main outcome at 5 years will be a composite of death or survival with severe disability in at least one of six domains: cognition, neuromotor function, vision, hearing, behavior, and general health. Once this project is completed, caffeine will be one of the most rigorously evaluated neonatal therapies.

Original languageEnglish
Pages (from-to)208-213
Number of pages6
JournalBiology of the Neonate
Volume88
Issue number3
DOIs
Publication statusPublished - Sep 2005
Externally publishedYes

Keywords

  • Apnea of prematurity
  • Caffeine
  • Controlled clinical trial
  • Disability
  • Methylxanthine
  • Very low birth weight infant

Cite this

@article{8b78450028aa4b1eabb48551b03ca754,
title = "Methylxanthine therapy for apnea of prematurity: Evaluation of treatment benefits and risks at age 5 years in the international Caffeine for Apnea of Prematurity (CAP) trial",
abstract = "Methylxanthine therapy reduces the frequency of apnea and the need for mechanical ventilation. Recent research has raised concerns about the safety of methylxanthines in very preterm infants. Possible adverse effects include poor growth, worsening of hypoxic-ischemic brain damage and abnormal childhood behavior. Over 2,000 infants with birth weights 500-1,250 g have been randomized in the international placebo-controlled Caffeine for Apnea of Prematurity (CAP) trial to examine the long-term efficacy and safety of methylxanthine therapy for the management of apnea of prematurity. Additional therapies such as continuous positive airway pressure were used as necessary to control apneic attacks. At 18 months we measure the combined rate of death or survival with one or more of the following impairments: cerebral palsy, cognitive deficit, blindness and deafness. This outcome was chosen because of the need to evaluate the impact of common neonatal therapies beyond discharge from the intensive care unit. However, several potential long-term consequences of methylxanthine therapy may not become apparent until the study cohort reaches pre-school age. We will therefore extend the follow-up to age 5 years. The main outcome at 5 years will be a composite of death or survival with severe disability in at least one of six domains: cognition, neuromotor function, vision, hearing, behavior, and general health. Once this project is completed, caffeine will be one of the most rigorously evaluated neonatal therapies.",
keywords = "Apnea of prematurity, Caffeine, Controlled clinical trial, Disability, Methylxanthine, Very low birth weight infant",
author = "Barbara Schmidt and {for the CAP 5-Year Steering Committee}",
year = "2005",
month = "9",
doi = "10.1159/000087584",
language = "English",
volume = "88",
pages = "208--213",
journal = "Biology of the Neonate",
issn = "0006-3126",
number = "3",

}

Methylxanthine therapy for apnea of prematurity : Evaluation of treatment benefits and risks at age 5 years in the international Caffeine for Apnea of Prematurity (CAP) trial. / Schmidt, Barbara; for the CAP 5-Year Steering Committee.

In: Biology of the Neonate, Vol. 88, No. 3, 09.2005, p. 208-213.

Research output: Contribution to journalReview ArticleResearchpeer-review

TY - JOUR

T1 - Methylxanthine therapy for apnea of prematurity

T2 - Evaluation of treatment benefits and risks at age 5 years in the international Caffeine for Apnea of Prematurity (CAP) trial

AU - Schmidt, Barbara

AU - for the CAP 5-Year Steering Committee

PY - 2005/9

Y1 - 2005/9

N2 - Methylxanthine therapy reduces the frequency of apnea and the need for mechanical ventilation. Recent research has raised concerns about the safety of methylxanthines in very preterm infants. Possible adverse effects include poor growth, worsening of hypoxic-ischemic brain damage and abnormal childhood behavior. Over 2,000 infants with birth weights 500-1,250 g have been randomized in the international placebo-controlled Caffeine for Apnea of Prematurity (CAP) trial to examine the long-term efficacy and safety of methylxanthine therapy for the management of apnea of prematurity. Additional therapies such as continuous positive airway pressure were used as necessary to control apneic attacks. At 18 months we measure the combined rate of death or survival with one or more of the following impairments: cerebral palsy, cognitive deficit, blindness and deafness. This outcome was chosen because of the need to evaluate the impact of common neonatal therapies beyond discharge from the intensive care unit. However, several potential long-term consequences of methylxanthine therapy may not become apparent until the study cohort reaches pre-school age. We will therefore extend the follow-up to age 5 years. The main outcome at 5 years will be a composite of death or survival with severe disability in at least one of six domains: cognition, neuromotor function, vision, hearing, behavior, and general health. Once this project is completed, caffeine will be one of the most rigorously evaluated neonatal therapies.

AB - Methylxanthine therapy reduces the frequency of apnea and the need for mechanical ventilation. Recent research has raised concerns about the safety of methylxanthines in very preterm infants. Possible adverse effects include poor growth, worsening of hypoxic-ischemic brain damage and abnormal childhood behavior. Over 2,000 infants with birth weights 500-1,250 g have been randomized in the international placebo-controlled Caffeine for Apnea of Prematurity (CAP) trial to examine the long-term efficacy and safety of methylxanthine therapy for the management of apnea of prematurity. Additional therapies such as continuous positive airway pressure were used as necessary to control apneic attacks. At 18 months we measure the combined rate of death or survival with one or more of the following impairments: cerebral palsy, cognitive deficit, blindness and deafness. This outcome was chosen because of the need to evaluate the impact of common neonatal therapies beyond discharge from the intensive care unit. However, several potential long-term consequences of methylxanthine therapy may not become apparent until the study cohort reaches pre-school age. We will therefore extend the follow-up to age 5 years. The main outcome at 5 years will be a composite of death or survival with severe disability in at least one of six domains: cognition, neuromotor function, vision, hearing, behavior, and general health. Once this project is completed, caffeine will be one of the most rigorously evaluated neonatal therapies.

KW - Apnea of prematurity

KW - Caffeine

KW - Controlled clinical trial

KW - Disability

KW - Methylxanthine

KW - Very low birth weight infant

UR - http://www.scopus.com/inward/record.url?scp=26444537383&partnerID=8YFLogxK

UR - https://www-karger-com.ezproxy.lib.monash.edu.au/Article/Pdf/87584

U2 - 10.1159/000087584

DO - 10.1159/000087584

M3 - Review Article

VL - 88

SP - 208

EP - 213

JO - Biology of the Neonate

JF - Biology of the Neonate

SN - 0006-3126

IS - 3

ER -